ADMA Q3 2021 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$21M+101.2% YoY

Gross Profit

$385,3371.9% margin

Operating Income

-$14M-69.8% margin

Net Income

-$18M-85.7% margin

EPS (Diluted)

$-0.13

QoQ Revenue Growth

+16.0%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$16M

Stock-Based Comp.

$688,274

Balance Sheet

Total Assets

$239M

Total Liabilities

$136M

Stockholders' Equity

$103M

Cash & Equivalents

$34M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$21M	$10M	+101.2%
Gross Profit	$385,337	-$2M	+124.4%
Operating Income	-$14M	-$14M	-4.6%
Net Income	-$18M	-$17M	-4.7%

Revenue Segments

Product Revenue

$21M100%

License Revenue

$35,7080%